| Document |
Document Title |
|
WO/1997/025309A1 |
Derivatives of mutiline of formula (1A) and pharmaceutically acceptable salts and derivatives thereof, in which R1 is ethyl or vinyl, Y is a carbamoyloxy group, in which the N-atom is unsubstituted, or mono- or di-substituted, are useful...
|
|
WO/1997/025319A1 |
Compounds of formula (I) in which R1 is a substituted phenyl group and X is O, S, SO or SO2, are well suited for use as herbicides.
|
|
WO/1997/024353A1 |
The disclosure relates to substituted 6-H-1,3,4-thiadiazine-2-imines of general formula (I), in which (II) represents a morpholine, thiomorpholine, piperidine, pyrrolidine or hexamethylene imine fragment, or to the pharmacologically acce...
|
|
WO/1997/024418A1 |
A homogenous product is formed by heating at a temperature in the range of from 50� to 150 �C a mixture of a benzotriazole and a 2,5-dihydrocarbyldithio-1,3,4-thiadiazole.
|
|
WO/1997/024118A1 |
The compounds according to the invention are substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides of formula (I) herein which exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical co...
|
|
WO/1997/024352A1 |
The disclosure relates to substituted 6H-1,3,4-thiadiazine-2-amines of general formula (I), in which Ar stands for phenyl which can be substituted with one or more atoms of chlorine, bromine, C1-C4 alkoxy or C1-C4 alkyl groups; and (a) r...
|
|
WO/1997/023471A1 |
Thiadiazols have the formula (I), in which the index and the substituents have the following meaning: n equals 1, 2, 3, 4 or 5, whereas the R substituents may differ from each other when n is higher than 1; R stands for alkyl, alkenyl or...
|
|
WO/1997/023476A1 |
Cyclic sulphones of formula (I) are disclosed, in which: R1 and R2 each independently of one another stand for H, A, CF3, CH2F, CHF2, C2F5, Hal, OH, OA, NH2, NHA, NA2, NO2 or CN; X stands for CR4R5, C=Z, O, S, NH, NA or NR3; Y stands for...
|
|
WO/1997/020840A1 |
The invention relates to 1,2,3-thiadiazole carboxylic acid (thio)esters of the formula (I), in which A is a single bond or alkane diyl substituted optionally by aryl or aryl halide, wherein the alkane diyl chain can be broken by oxygen o...
|
|
WO/1997/020830A1 |
The invention relates to new dithiazoldioxides of the general formula (I), in which R is hydrogen or optionally substituted alkyl, alkenyl or alkinyl, and Ar is optionally substituted aryl. The invention also relates to a method for the ...
|
|
WO/1997/020819A1 |
The present invention provides a composition and method for treating pain using Selected Muscarinic Compounds and one or more compounds selected from the group consisting of Nonsteroidal Anti-inflammatory drugs, acetaminophen, opioids, a...
|
|
WO/1997/020465A1 |
The invention relates to the use of partially known 1,2,3-thiadiazole carboxylic acid (thio)esters of formula (I), in which R1 is hydrogen, optionally substituted alkyl or optionally substituted aryl; R2 is optionally substituted alkyl, ...
|
|
WO/1997/017962A1 |
The present invention provides a method for treating anxiety in humans using azacyclic or azabicyclic compounds.
|
|
WO/1997/016433A1 |
The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, includin...
|
|
WO/1997/016177A1 |
A novel cathepsin K crystalline structure is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial character...
|
|
WO/1997/015308A1 |
Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15�, are effective...
|
|
WO/1997/015567A1 |
Disclosed are five-membered heterocycles of general formula (I) in which X1-X5 have the meanings indicated in claim 1, the tautomers and stereoisomers thereof including mixtures thereof, and the salts thereof especially those salts with ...
|
|
WO/1997/014687A1 |
The disclosure concerns fluoromethoxyacrylic acid derivatives of formula (I), in which Ar stands for substituted aryl and Q for optionally substituted alkoxy, and the use of these compounds as pest-control agents. The disclosure also rel...
|
|
WO/1997/013747A1 |
The disclosure concerns oxyamino oxime ethers of formula (I), wherein: X is NOCH3, CHOCH3, CHCH3; Y is O or NZ, Z being H or alkyl; R1 is H or alkyl; R2 is cyano, nitro, trifluoromethyl, halogen, alkyl or alkoxy, m = 0, 1 or 2 and the gr...
|
|
WO/1997/013758A1 |
Novel compounds of formula (I), wherein R1, R2, R3 and Y have the meanings indicated in claim 1, and their salts, have endothelin-receptor antagonistic properties.
|
|
WO/1997/012863A1 |
Compounds represented by general formula (I), wherein R1 represents an optionally substituted heterocyclic group; R2 represents an optionally substituted aryl or heterocyclic group; R3 represents hydrogen, alkyl, alkenyl or alkynyl; R4 r...
|
|
WO/1997/010825A1 |
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective 'beta'3 adrenergic receptor agonists useful in the treatment ...
|
|
WO/1997/010228A1 |
Compounds of formula (I) where: each R1 and each R2 is an optionally substituted alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl or amino group, the group Y-X-, halogen, cyano, nitro, acyl, heterocyclyl, heterocyclyloxy, aryl or arylox...
|
|
WO/1997/008150A1 |
The present invention relates to substituted cyclic ureas and analogs thereof of formula (I), wherein T is selected from: -N(R22)C(=Z)N(R23)-; -N(R22)C(=Z)C(=Z)N(R23)-; -N(R22)S(=Z')N(R23)-; -N(R22)S(=Z')2N(R23)-; or -N(R22)P(=O)(R24a)N(...
|
|
WO/1997/008160A1 |
The invention relates to novel N-(1-Isopropyl-2-methyl-1-propenyl)heteroaryloxyacetamides of formula (I) in which Het is optionally benzannellated and optionally substituted heteroaryl; and R is optionally substituted alkyl. It also rela...
|
|
WO/1997/005124A1 |
The invention concerns benzene derivatives of the formula (I) in which n is 0, 1, or 2, X is nitro or amino, Z is a direct bond or optionally substituted alkylene, Y is vinyl or a group of the formula C2H4-Q in which Q is hydroxy or a gr...
|
|
WO/1997/003945A1 |
Compounds of formula (I) wherein: R1 is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, (CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR6: W is alkynyl or 2 carbon atoms; R3 is H or R7; Z is C(O)R13, (CH2)0-1C(O)OR13, (CH2)0-1C(O)NR10R13, (CH2)0...
|
|
WO/1997/003953A1 |
Compounds of the formula (I) in which A is oxygen, sulphur or NH; B is a group of the formula (IIa) or (IIb); and the other variables have the meaning given in claim 1, may be used as inhibitors of the enzyme cyclo-oxygenase II.
|
|
WO/1997/003950A1 |
Ether derivatives having the general formula (I), several processes for preparing the same and their use as fungicides are disclosed, as well as intermediate products and several processes for preparing the same. In the formula (I): Ar s...
|
|
WO/1997/000853A1 |
Compounds of general formula (I), salts thereof or hydrates thereof wherein (a) represents (b) or (c), for example, the compounds (d) and (e), which are useful as a PGD2 antagonist and thus usable in, for example, a remedy for systemic m...
|
|
WO/1996/040745A2 |
Amino acid amides of 5-amino-1,3,4-thiadiazole-2-thione are disclosed. These compounds inhibit matrix metalloproteinase enzymes and cartilage degradation. Methods of treating diseases caused by over-activity of matrix metalloproteinases,...
|
|
WO/1996/039978A1 |
A method for treating victims of cerebral edema is presented that includes the intravenous injection of acetazolamide (A.K.A., DIAMOX), which is a readily-available and often-prescribed diuretic. Such edema, or brain swelling may be caus...
|
|
WO/1996/039400A1 |
Compounds having formulae (I) to (VI) wherein X is a substituted (hetero)aryl group and R1-R6 are various possible substituents, are corticotropin-releasing factor (CRF) receptor antagonists.
|
|
WO/1996/038150A1 |
The present invention relates to novel 4.4-(disubstituted)cyclohexan-1-ols monomers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhib...
|
|
WO/1996/038430A1 |
The present invention relates to a process for making intermediates useful for preparing therapeutically active azacyclic or azabicyclic compounds.
|
|
WO/1996/038431A1 |
The present invention relates to a process for making intermediates useful for preparing therapeutically active azacyclic or azabicyclic compounds.
|
|
WO/1996/037480A1 |
Compounds of general formula (I) in which R is cyano, halogen, alkyl or alkoxy; n is 0, 1 or 2, in which the components R may be different if n is 2; Het is a 5-membered heteroaromatic substance containing three nitrogen atoms or two nit...
|
|
WO/1996/036595A1 |
3,4-Disubstituted benzenesulphonamides of general formula (i), in which R3 represents arylalkyl, heteroarylalkyl, heterocycloalkyl, COR7, S(O)mR7, optionally substituted C1-6 alkyl, R4 represents arylalkyl, heteroarylalkyl or heterocyclo...
|
|
WO/1996/035669A1 |
Described are (het)aryloxy-, -thio-, aminocrotonates of formula (I) in which the substituents are defined as follows: U is oxygen, sulphur or amino; V is oxygen, sulphur, amino or alkylamino; X, Y, Z, independently of each other, are =N-...
|
|
WO/1996/034854A1 |
'beta'-azidoethane sulfonylazide having the formula N3CH2CH2SO2N3 is disclosed, as well as a process for preparing the same and its use in processes for preparing taurinamide or taurolidine extracted from taurinamide in a manner known pe...
|
|
WO/1996/033159A1 |
The present invention provides a compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de...
|
|
WO/1996/031463A1 |
The invention pertains to substituted cycloalkenes of general formula (I) and several methods of preparing them, as well as intermediate products and several methods for preparing them. In this formula (I), E stands for methylidene or ni...
|
|
WO/1996/030333A1 |
Compounds of formula (I), wherein X represents a single bond, O, S or CR9R10 where R9 and R10 each independently represent a hydrogen atom or a C1-4alkyl group; R1a, R1b and R1c each independently represent a substituent selected from: a...
|
|
WO/1996/029871A2 |
A method for using a compound represented by general formula (I) (wherein R1 and R2 are the substituents, respectively, defined in the specification) for agricultural and horticultural disease control, and a composition used in said method.
|
|
WO/1996/030351A1 |
Liquid crystal compounds have the general formula (I) X(-Y-A-Y-M-Y-B)n, in which X stands for an aliphatic, aromatic, alkenyl-alkinyl or cycloaliphatic residue; n equals 2, 4 or 5; the symbols Y represent independently from each other a ...
|
|
WO/1996/030352A1 |
The invention concerns liquid crystal compounds of general formula (I) X(-Y-A-Y-M-Y-B)n in which X is an n-valent aliphatic, aromatic or cycloaliphatic group or an n-valent alkenyl or alkinyl group; n is one of the numbers 2, 4 or 5, the...
|
|
WO/1996/029305A1 |
Compounds of formula (I) wherein either a) Z is N, Y is O or NH and W is O, S, SO or SO2, or b) Z is CH, Y is O and W is S, SO or SO2; and R is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, phenyl or heterocyclyl, each of which is o...
|
|
WO/1996/028434A1 |
The invention relates to novel fluorothiadiazolyl oxyacetamides of the formula (I) in which R1 is hydrogen or possibly substituted alkyl, alkenyl, alkinyl or arylalkyl, R2 is possibly substituted alkyl, alkoxy, alkenyl, alkenyloxy, alkin...
|
|
WO/1996/027584A1 |
An energy-sensitive (e.g., thermal, radiation or photosensitive) initiator, curative, and/or catalytic salt that has an anion comprising a tris-(highly fluorinated alkylsulfonyl)methide, tris-(fluorinated arylsulfonyl)methide, bis-(highl...
|
|
WO/1996/026200A1 |
The invention concerns benzoyl derivatives of formula (I) in which the substituents have the following meanings: L and M represent hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C1-C4 alkoxy (these groups being optionally substitut...
|
